Lindsey Shapiro, PhD,  science writer—

A significant proportion of people diagnosed with drug-induced angioedema due to using certain blood pressure medications — namely angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin 2 receptor blockers (ARBs) — were misdiagnosed, according to a recent report from France. These patients, who continued to experience recurrent angioedema attacks more than…

Changes in the properties of endothelial cells that line blood vessels may underlie increases in the numbers of circulating immune neutrophils in people with hereditary angioedema (HAE), according to a recent report. Although neutrophils are more abundant and activated in the blood of people with HAE types 1 and…

The Phase 3 clinical trial of oral sebetralstat as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE) has reached its target enrollment of 114 patients. Findings from the global KONFIDENT study (NCT05259917) are expected by year’s end, according to the therapy’s developer,…

Authorities in Chile have approved Orladeyo (berotralstat) to prevent swelling attacks in hereditary angioedema (HAE) patients 12 and older, marking the therapy’s first marketing authorization in a Latin American country. The preventive, or prophylactic, oral therapy from BioCryst Pharmaceuticals holds similar approvals in the U.S.,…

Insurance issues significantly affected the physical, psychological, and financial health of people with hereditary angioedema (HAE) in the U.S., according to a recent patient survey. Patients reported that health insurance delays and coverage denials led to more frequent HAE attacks, urgent care visits, missed work or school, and greater…

Long-term treatment with Takhzyro (lanadelumab) was associated with quality of life gains among people with hereditary angioedema (HAE) who participated in the HELP open-label long-term extension (OLE) study. The study’s participants, who either rolled over from the Phase 3 HELP trial (NCT02586805), or were newly enrolled in…

Astria Therapeutics intends to move directly into a pivotal trial to support STAR-0215’s regulatory approval for hereditary angioedema (HAE) if proof-of-concept results from the ongoing Phase 1b/2 trial are positive, the company has announced. Initial results from the trial, called ALPHA-STAR (NCT05695248), are expected in mid-2024. With…

Garadacimab, a preventive treatment candidate from CSL Behring, led to significant and clinically meaningful reductions in swelling attacks in patients with hereditary angioedema (HAE), according to published data from the Phase 3 VANGUARD clinical trial. The company expects to seek garadacimab’s approval from global health authorities later this…

The U.S. Food and Drug Administration (FDA) has extended the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) starting at age 2. Takhzyro, available to patients ages 12 and older in the U.S. since 2018, is now the only approved treatment to prevent HAE swelling…

Rates of prescriptions for Firazyr (icatibant), an on-demand treatment to control swelling episodes in people with hereditary angioedema (HAE), have increased in recent years, especially for women, according to a study from Sweden. While the finding could mean that more patients have poorly-controlled disease, more prescriptions for the…